Clinical Trial Results: Fluvoxamine

In a CETF-sponsored clinical trial, early treatment of COVID-19 with fluvoxamine dramatically reduced hospitalization rates by over 90%.
‍Read more
The Phase 3 trial is now open to anyone in the US. Learn more
‍

About
Drugs
Take action
FAQ
Fluvoxamine
Donate
Medical Breakthrough

75%

Camostat Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla

Expedite the fight

The shortest path to getting life back to normal now is with early treatment

What is the COVID-19 Early Treatment Fund?
View more CETF
Two women talking and holding a beer mug
A afro american family hugging each other
friends smiling and talking in the middle of the crowd
A baseball fans watching the game in a stadium
a top view from a dinner table. people passing a plate of fruits to each other.

Overview

We're on a mission to find an existing drug or drug combination that, when given early, reduces hospitalization and fatality rates by 75% or more.
Learn more
The Problem

Nearly all funded clinical trials today are focused on slow or ineffective solutions

1

New drugs/vaccines take a long time to develop and an even longer time to distribute.

2

Repurposing existing drugs is much faster. Unfortunately, nearly all clinical trials of repurposed drugs have been conducted via inpatient trials

  • These require participants to be hospitalized before joining the trial

  • Viruses respond best when treated early, not late.

3

‍As a result, inpatient trials have had limited success because patients receive treatments too late

Learn more ›
Our Solution

Identify early treatments by funding outpatient clinical trials of the most promising existing drugs

Clinical trials ›

Promising Drugs

Learn about promising early treatment drugs such as Fluvoxamine, and the exciting clinical trial results
Learn more
Who we are

We are a team of the world’s top scientists, doctors, technologists and philanthropists working, to identify meaningful treatments for COVID-19, that could be used ASAP

Chairman of CETF SAB; immunologist and virologist working on HIV at Johns Hopkins University
Robert Siliciano, M.D., Ph.D.
Johns Hopkins University
Chairman of CETF SAB; immunologist and virologist working on HIV at Johns Hopkins University
Professor of cell biology; virologist and coronavirus expert at Johns Hopkins University
Carolyn Machamer, Ph.D.
Johns Hopkins University
Professor of cell biology; virologist and coronavirus expert at Johns Hopkins University
Professor emeritus of medicine, molecular biology/genetics and
medicine, Johns Hopkins
Stephen Desiderio, M.D, Ph.D.
Johns Hopkins University
Professor emeritus of medicine, molecular biology/genetics and
medicine, Johns Hopkins
Professor emeritus of pathology and medicine; director, University of California, San Diego Center for AIDS Research and Research Center for AIDS and HIV Infection at VA San Diego Healthcare System
Doug Richman, M.D.
University of California
Professor emeritus of pathology and medicine; director, University of California, San Diego Center for AIDS Research and Research Center for AIDS and HIV Infection at VA San Diego Healthcare System
Physician-scientist; HIV clinical trials expert, Harvard Medical School
Raj Gandhi, M.D.
Harvard University
Physician-scientist; HIV clinical trials expert, Harvard Medical School
Professor of medicine (infectious diseases), Howard Taylor Ricketts; HIV virology expert and director, HIV Translational Research Center at Northwestern
Rich D'Aquila, M.D.
Northwestern University
Professor of medicine (infectious diseases), Howard Taylor Ricketts; HIV virology expert and director, HIV Translational Research Center at Northwestern
Full scientific advisory board ›

Who We Are

We are a team of the world’s top scientists, doctors, technologists and philanthropists working, to identify meaningful treatments for COVID-19, that could be used ASAP. Our hand-picked scientific advisory board reviews each credible grant proposal.

full scientific advisory board ›
Robert Siliciano
Immunologist/virologist working on HIV at Johns Hopkins
Carolyn Machamer
Virologist and coronavirus expert at Johns Hopkins
Stephen Desiderio
Professor Emeritus, Immunology and molecular biology, John Hopkins
Richard Whitley
Associate director for drug discovery and development, University of Alabama
Rich D'Aquila
HIV virology and clinical infectious disease expert at Northwestern
Raj Gandhi
Physician scientist, HIV clinical trials expert at Harvard
full SCIENTIFIC ADVISORY board ›

What medical experts are saying

“I strongly support the work CETF is doing. Testing the top antiviral drugs must be our #1 priority. It is critical to raise funds to enable this testing to take place as soon as possible.”

Siddhartha Mukherjee, MD, PhD

Pulitzer Prize winning author
Researcher & Physician
Columbia University

"It's invigorating to see that CETF is working to fund COVID-19 research in a rapid and collaborative manner and focusing their resources on strategies that are likely to have the greatest immediate impact."

Chetan Bettegowda

Professor of Neurosurgery and Oncology
Johns Hopkins Medical Institutions

"We agree with CETF that preventative approaches have the best chance of alleviating suffering and death from COVID-19 and commend them for supporting these much needed lines of investigation."

Bert Vogelstein

Professor of Oncology
Johns Hopkins Medical Institutions

More testimonials ›
Donate to the
COVID-19 Early Treatment Fund today
Donate
Find a Trial
Apply for Funding

The COVID-19 Early Treatment Fund (CETF) is administered by Rockefeller Philanthropy Advisors, a 501(c)(3) public charity (EIN: 13-3615533). All donations to CETF are tax deductible and go exclusively towards funding outpatient trials.

We use cookies to offer you a better browsing experience and to analyze site traffic. By continuing to use our website, you consent to the use of these cookies.
ok